Tailored MgSO4 Supplementation to Reduce Complications in Pediatric Heart Surgery

NCT ID: NCT06564376

Last Updated: 2024-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-20

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lay Summary

This study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. This will let doctors choose the right dose of MgSO4. MgSO4 is a magnesium supplement. Taking MgSO4 after heart surgery helps children. For each child, it is best to personalize MgSO4 dose. This is based on the amount of magnesium in blood. This study will test two ways of personalizing MgSO4 dose.

In the blood, there are two kinds of magnesium. Usually, blood magnesium tests measure both forms together. This does not say anything about active magnesium. This study will measure the two forms separately. Then, MgSO4 will be given based on either the active or whole magnesium. Measuring active magnesium is good. Active magnesium levels change faster than total. That means active magnesium tests may better protect children. Also, active magnesium has more of an impact on heart and kidney function. Focusing on the active form will help these organs stay healthy.

To test how well the MgSO4 is working, heart and kidneys will be examined. After surgery, certain harmful heart rhythms can occur. The types and number of harmful rhythms will be studied. Kidney problems can also happen after heart surgery. Kidney health will be studied. To help understand how active magnesium works, further tests will be done. These tests will look for evidence of poor health in the cells that make up the heart, kidney, and blood.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypothesis: Modulating patient Mg levels based on ionized Mg will have clinical and functional benefits over using total Mg, due to the increased sensitivity and specificity of the ionized form. The primary goal of this project is to experimentally test the benefit of maintaining ionized normomagnesemia after cardiac surgery in children with regard to renal function and arrhythmia incidence . A secondary goal is to develop a model for predicting AKI after cardiac surgery in children, using a machine learning approach to understand interrelationships between magnesium-dependent physiological processes (Figure 1B). Successful completion of this project will define the utility and positionality of ionized Mg as an actor in pediatric post-surgical AKI, and its synergy with established clinical and physiological outcomes.

Aim 1: Investigating use of ionized Mg for Mg repletion therapy

In this aim, patients will be randomized to one of two strategies for Mg repletion therapy, one utilizing ionized Mg, the other using total Mg. The effects of these two strategies on clinical and physiological outcomes will be measured, as will the durability of the different Mg repletion strategies in preventing or correcting hypomagnesemia. 96 participants will be enrolled in this study. Because arrhythmia risk and AKI risk are dramatically stratified by age, subjects will be age-matched into the following groups: 0-1 month, 2 months to 2 years, 3- 9 years, 9 years -18 years. Children will be randomly assigned to one of two Mg repletion strategies. Randomization will occur after consenting and reaffirmation that the child/family/guardian still continue to agree to participate in the study. For each age group there will be 24 sealed envelopes that identify which treatment strategy for magnesium repletion they will be assigned (Total or ionized). This envelope will be opened at SBAR prior to the induction of anesthesia. Magnesium levels will be drawn and sent as per standard protocol. All patients will have ionized magnesium levels obtained with every blood gas, but only those in the ionized group will the physicians see and treat the magnesium based upon that value. Patients with hypomagnesemia ( value less than or equal to 1.8 Mg/dl in the total Magnesium group will be given MgSO4 at a standard dose of 50 mg/kg over 1 hour beginning at the intraoperative stage and at every subsequent timepoint where an individual's lab values show hypomagnesemia (Table 1). Those patients in the ionized magnesium group will be dosed according to Table 1 beginning at the intraoperative stage and at every subsequent timepoint where an individual's lab values show hypomagnesemia (Table 1). Study participants will be blinded to treatment group. Researchers will not be blinded at the time of MgSO4 administration due to logistical pharmacy requirements. All data analysis including ECG analysis will be performed by blinded researchers. In one arm, Mg repletion will be titrated using ionized Mg as a measure, maintaining an ionized Mg level of 0.98-1.46 mg/dl. In the other, Mg repletion will be titrated using total Mg as a measure. Due to reagents used by WVU labs, the reference range for total Mg is 1.9-3.1 mg/dL; patients in the total Mg arm will be maintained in this range. To ensure proper electrolyte balance, Ca2+, K+, and Na+ will be maintained within appropriate ranges using standard methodology.

Mg level will be measured on all arterial blood gases. Mg will be measured at least: pre-incision, at the completion of the procedure, and twice a day for 48 hours after surgery. In order to assess differences in post-treatment Mg maintenance after cessation of therapy, ionized and total Mg levels will also be measured 4 hours after Mg supplementation.

Urinary NGAL and Creatinine will be measured pre-bypass, 2 hours after bypass and 24 hours after bypass to assess for renal injury.

Clinical outcomes to be measured include:

1. Urine output, measured hourly for 48 hours after surgery.
2. Blood lactate, measured at least daily (standard of care).
3. Time to extubation.
4. Occurrence of non-sinus cardiac rhythms, with special attention given to accelerated junctional rhythms.

Magnesium dosing Total Mg (mg/dL) Less than or equal to 1.8 MgSO4 dose 50 mg/kg Ionized Mg Observed Mg(Mg/dL) MgSO4 dose 1.3 10 mg/kg - 1 hr 1.2 20 mg/kg - 1 hr 1.0 30 mg/kg - 1 hr 0.9 40 mg/kg - 1 hr 0.8 50 mg/kg - 1hr

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AKI - Acute Kidney Injury Arrythmia Congenital Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Total magnesium

Magnesium dosing based on total Mg blood level

Group Type OTHER

total magnesium

Intervention Type DIAGNOSTIC_TEST

Treatment based on total Magnesium

ionized Magnesium

Magnesium dosing based upon ionized Mg level

Group Type ACTIVE_COMPARATOR

ionized magnesium

Intervention Type DEVICE

Treatment based on ionized magnesium

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

total magnesium

Treatment based on total Magnesium

Intervention Type DIAGNOSTIC_TEST

ionized magnesium

Treatment based on ionized magnesium

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children undergoing cardiac surgery utilizing cardiopulmonary bypass

Exclusion Criteria

* Children undergoing cardiac surgery without cardiopulmonary bypass
* Children with Renal disease
* Children with pre-existing arrhythmia
* Children on anti-arrhythmia medication
Minimum Eligible Age

0 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

West Virginia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

David Rosen, MD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David A Rosen, MD

Role: PRINCIPAL_INVESTIGATOR

West Virginia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

West Virginia University

Morgantown, West Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

David A Rosen, MD

Role: CONTACT

3045984000 ext. 4122

Frank L Casey, MD

Role: CONTACT

3042931017

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

s42qwux9

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.